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Synthesis and Characterization of Cytidine
Derivatives that Inhibit the Kinase IspE of the
Non-Mevalonate Pathway for Isoprenoid
Biosynthesis
Christine M. Crane,[a] Anna K. H. Hirsch,[a] Magnus S. Alphey,[b] Tanja Sgraja,[b]
Susan Lauw,[c] Victoria Illarionova,[c] Felix Rohdich,*[c] Wolfgang Eisenreich,[c]
William N. Hunter,*[b] Adelbert Bacher,[c] and FranÅois Diederich*[a]
Introduction
The non-mevalonate pathway was discovered in the early
1990s in the research groups of Rohmer, Arigoni, and Sahm
and uses seven enzymes in the assembly of the essential iso-
prenoid precursor molecules, isopentenyl diphosphate (IPP)
and dimethylallyl diphosphate (DMAPP), starting from pyruvate
and glyceraldehyde-3-phosphate (Scheme 1).[1] The pathway is
used exclusively by many pathogens, such as the tuberculosis-
causing M. tuberculosis[2] and the malaria-causing P. falci-
parum,[3, 4] but not by humans. Taken together, tuberculosis[5]
and malaria[6] are responsible for an estimated 300–500 million
new infections and 3 million deaths annually. Efforts to combat
these diseases are hampered by the rapid emergence of multi-
drug resistance in both organisms.[6,7]
Inhibition of the enzymes of the non-mevalonate pathway
has been recognized as an alternative approach for the devel-
opment of potential next-generation chemotherapeutics for
the treatment of malaria and tuberculosis. Thus, Jomaa et al.
showed that fosmidomycin [OHCN(OH)ACHTUNGTRENNUNG(CH2)3PO3H2], a
potent inhibitor of the second enzyme in the pathway, IspC (1-
deoxy-d-xylulose-5-phosphate reductoisomerase, EC 1.1.1.267),
cures malaria in rodents,[4] and this compound is being tested
in clinical trials.[8]
A growing number of published X-ray crystal structures of
the constituent enzymes of the non-mevalonate pathway have
paved the way for the exploitation of these enzymes as targets
in structure-based drug design.[9] If such a lead generation
strategy focuses on several enzymes of the same biochemical
pathway, chances increase for the identification of active li-
gands with the potential of inhibiting more than one enzyme
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The enzymes of the non-mevalonate pathway for isoprenoid bio-
synthesis are attractive targets for the development of novel
drugs against malaria and tuberculosis. This pathway is used ex-
clusively by the corresponding pathogens, but not by humans. A
series of water-soluble, cytidine-based inhibitors that were origi-
nally designed for the fourth enzyme in the pathway, IspD, were
shown to inhibit the subsequent enzyme, the kinase IspE (from
Escherichia coli). The binding mode of the inhibitors was verified
by co-crystal structure analysis, using Aquifex aeolicus IspE. The
crystal structures represent the first reported example of a co-
crystal structure of IspE with a synthetic ligand and confirmed
that ligand binding affinity originates mainly from the interac-
tions of the nucleobase moiety in the cytidine binding pocket of
the enzyme. In contrast, the appended benzimidazole moieties of
the ligands adopt various orientations in the active site and es-
tablish only poor intermolecular contacts with the protein. De-
fined binding sites for sulfate ions and glycerol molecules, com-
ponents in the crystallization buffer, near the well-conserved ATP-
binding Gly-rich loop of IspE were observed. The crystal structures
of A. aeolicus IspE nicely complement the one from E. coli IspE
for use in structure-based design, namely by providing invaluable
structural information for the design of inhibitors targeting IspE
from Mycobacterium tuberculosis and Plasmodium falciparum.
Similar to the enzymes from these pathogens, A. aeolicus IspE di-
rects the OH group of a tyrosine residue into a pocket in the
active site. In the E. coli enzyme, on the other hand, this pocket
is lined by phenylalanine and has a more pronounced hydropho-
bic character.
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from this pathway, thereby generating valuable information on
the binding modes of the various proteins. This article provides
a strong example in support of such a “one-pathway-multi-
target” strategy.
Our research group has focused on the structure-based
design of inhibitors of two central enzymes in the pathway,
IspE (4-diphosphocytidyl-2C-methyl-d-erythritol kinase,
EC 2.7.1.148)[10] and IspF (2C-methyl-d-erythritol-2,4-cyclodi-
phosphate synthase, EC 4.6.1.12) (Scheme 1).[11] IspE is a kinase
that catalyzes the phosphorylation of the 2-OH group of 4-di-
phosphocytidyl-2C-methyl-d-erythritol (CDP-ME), producing 4-
diphosphocytidyl-2C-methyl-d-erythritol-2-phosphate (CDP-
ME2P) in an ATP- and Mg2+-dependent reaction (Scheme 1).[12]
In the next step of the pathway, IspF catalyzes the cyclization
of CDP-ME2P to the cyclic diphosphate 2C-methyl-d-erythritol-
2,4-cyclodiphosphate (MECDP).[13] We found the development
of low-molecular-weight, drug-like ligands very challenging:
the enzymes feature highly polar active sites with limited con-
cave hydrophobic surface, in accordance with the polar struc-
tures of their phosphate- and diphosphate-based substrates.
Correspondingly, most inhibitors of enzymes in the pathway
described in the literature feature phosphate or phosphonate
moieties.[14] Only recently, we described more drug-like ligands
for IspE and IspF that lack phosphate or phosphonate
groups.[10,11b]
We also initially targeted the structure-based design of in-
hibitors for IspD (4-diphosphocytidyl-2C-methyl-d-erythritol-4-
phosphate synthase, EC 2.7.7.60),[15] the enzyme that precedes
IspE in the non-mevalonate pathway and catalyzes the trans-
formation of 2C-methyl-d-erythritol-4-phosphate (ME-4P) into
CDP-ME using cytidine 5’-triphosphate (CTP) and Mg2+
(Scheme 1). As part of these efforts, which were eventually dis-
continued, we prepared the series of water-soluble, cytidine-
based derivatives ()-1–(+)-4 (Figure 1).
As IspE, similar to IspD, processes a cytidine-based substrate
(Scheme 1),[13] the compounds were also tested against the
kinase and shown to be moderately active inhibitors with Ki
(inhibition constant) values in the double-digit micromolar
range. Gratifyingly, the co-crystal structures of ()-1 and (+)-3
bound to IspE from the thermophile A. aeolicus could be
solved, and these structures revealed useful information for
structure-based design efforts targeting IspE from other organ-
isms such as M. tuberculosis and P. falciparum. Herein, we
report the synthesis of the new ligands, their affinity towards
IspE, and the co-crystal structures of ()-1 and (+)-3 in com-
plex with the kinase.
Results and Discussion
Synthesis of the inhibitors
The preparation of inhibitors ()-1–(+)-4 is shown in
Schemes 2 and 3. The exocyclic NH2 group of commercially
available (+)-cytidine was N-acylated, and the 2’- and 3’-OH
groups of the ribose moiety were protected as an acetonide,
affording ()-5. Mitsunobu reaction with phthalimide, using
Scheme 1. The non-mevalonate pathway for the biosynthesis of the C5 precursors to isoprenoids, IPP and DMAPP.
[1] ADP=adenosine 5’-diphosphate,
ATP=adenosine 5’-triphosphate, CDP-ME=4-diphosphocytidyl-2C-methyl-d-erythritol, CDP-ME2P=4-diphosphocytidyl-2C-methyl-d-erythritol-2-phosphate,
DMAPP=dimethylallyl diphosphate, DXS=1-deoxy-d-xylulose 5-phosphate synthase, IPP= isopentenyl diphosphate, MECDP=2C-methyl-d-erythritol-2,4-cy-
clodiphosphate.
Figure 1. Cytidine derivatives investigated as inhibitors of IspE.
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diisopropyl azodicarboxylate and triphenylphosphine in N,N-di-
methylformamide, afforded intermediate (+)-6 in good yield.
At this stage of the synthesis, it became necessary to convert
the acetyl into a more stable N-protecting group, as it was
found to react under the conditions of phthalimide cleavage,
which typically employs nucleophilic bases such as hydrazine,
methylamine, or n-butylamine. These bases can attack both
the acetamido moiety as well as the adjacent C4 of N-acetyla-
ACHTUNGTRENNUNGted cytosines (for atom labeling, see Scheme 2) to afford mix-
tures of products.[16] Deacetylation of (+)-6 was successful with
the use of ammonia in methanol/dichloromethane and afford-
ed cytidine derivative (+)-7 in good yield. The 4,4’-dimethoxy-
trityl group (DMTr, bis(4-methoxyphenyl) ACHTUNGTRENNUNG(phenyl)methyl) was
found to be the most suitable protecting group for the exocy-
clic NH2 group, as it effectively prevented nucleophilic attack
at C4 of cytosine. Subsequent reaction of (+)-7 with 4,4’-di-
ACHTUNGTRENNUNGmethoxytrityl chloride and triethylamine in dichloromethane
afforded (+)-8 in 85% yield. The phthalimide moiety was sub-
sequently transformed into primary amine (+)-9 in 87% yield
by using n-butylamine in methanol at 60 8C. Coupling of (+)-9
with 1H-benzimidazol-2-yl-acetic acid (10)[17] or commercially
available 2-benzimidazolepropionic acid (11), using O-benzo-
triazole-N,N,N’,N’-tetramethyluronium hexafluorophosphate
(HBTU), 1-hydroxybenzotriazole (HOBt), and triethylamine, fol-
lowed by acetonide and DMTr deprotection using 30% tri-
fluoroacetic acid in acetonitrile/water afforded ()-1 and (+)-3
as bis(trifluoroacetate) salts (Scheme 2).
Interestingly, the 1H NMR spectra of (+)-8 in CD3OD and
(+)-9 in CDCl3 recorded at 298 K showed the presence of two
conformers (Supporting Information Figures 1SI and 2SI, and
Tables 1SI and 2SI). In particular, the cytosine resonances of H
C5 and HC6 of (+)-8 and (+)-9 differ strongly in the two con-
formations (arbitrarily labeled A and B). The observation of the
conformational equilibrium is strongly solvent dependent (see
Supporting Information). The origin of the conformers, be it
from rotation about the C4Nexo bond (cis/trans) or the glycosi-
dic bond (syn/anti), as well as their structural assignment and
the thermodynamics and kinetics of the equilibrium, are under
further investigation.
The N-butyl derivatives ()-2 and (+)-4 were obtained start-
ing from tert-butylcarbamate-protected (+)-12 (Scheme 3),
which in turn was formed in excellent yield by protecting
(+)-7 with di-tert-butylcarbonate in dioxane/tetrahydrofuran at
70 8C. Surprisingly, cleavage of the phthalimide, using n-butyla-
mine in ethanol at 70 8C, provided (+)-13 in 80% yield. As
mentioned above, similar conversions have been noted to
occur on N-acetylated cytidines,[16] but always as minor side re-
actions. N-Butylated (+)-13 was immediately used after prepa-
ration, as it was found to rapidly decompose, even at 20 8C.
Coupling with 10 or 11 in the presence of HBTU, HOBt, and
triethylamine, followed by acetonide deprotection using 30%
trifluoroacetic acid in acetonitrile/water, afforded ()-2 and
(+)-4 as the bis-trifluoroacetate salts. Again, the 1H NMR spec-
tra at 298 K revealed the presence of two isomers (Supporting
Information Figures 3SI and 4SI).
Scheme 2. Synthesis of inhibitors ()-1 and (+)-3. a) Ac2O, MeOH, 75 8C!
20 8C, 18 h, 90%; b) HC ACHTUNGTRENNUNG(OEt)3, p-TsOH, acetone, 20 8C, 1 h, 83%; c) Phthali-
mide, Ph3P, DIAD, DMF, 20 8C, 18 h, 70%; d) 7n NH3 in MeOH, CH2Cl2/MeOH
1:1, 20 8C, 6 h, 85%; e) Et3N, DMTrCl, CH2Cl2, 20 8C, 1 h, 85%; f) nBuNH2, EtOH,
60 8C, 5 h, 87%; g) 10 or 11, HBTU, HOBt, Et3N, DMF, 0 8C!20 8C, 18 h;
h) TFA, CH3CN/H2O, 20 8C, 2 h, ()-1 (31%), (+)-3 (51%). DIAD=diisopropyl
azodicarboxylate, DMF=N,N-dimethylformamide, DMTrCl=dimethoxytrityl
chloride, HBTU=O-benzotriazole-N,N,N’,N’-tetramethyluronium hexafluoro-
phosphate, HOBt=1-hydroxybenzotriazole, Ph=phenyl, TFA= trifluoroacetic
acid, Ts= toluenesulfonyl.
Scheme 3. Synthesis of cytidine derivatives ()-2 and (+)-4. a) Boc2O, di-
ACHTUNGTRENNUNGoxane/THF, 70 8C, 6 h, 90%; b) i) nBuNH2, EtOH, 70 8C, 6 h, ii) 75 8C, 2 h, 82%;
c) 10 or 11, HBTU, HOBt, Et3N, DMF, 0 8C!20 8C, 18 h; d) TFA, CH3CN/H2O,
20 8C, 2 h, ()-2 (29%), (+)-4 (39%). Boc= t-butyloxycarbonyl.
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Biological results
The IC50 values (IC50=concentration of inhibitor at which 50%
maximum initial velocity is observed) for ()-1–(+)-4 were de-
termined using a photometric assay employing a complex set
of auxiliary enzymes and E. coli IspE (Table 1 and Supporting In-
formation Figure 5SI).[18] Whereas cytidine derivatives ()-1 and
(+)-3 were found to inhibit the kinase, the N-butyl derivatives
()-2 and (+)-4 were found to be completely inactive. Inhibi-
tion of the IspE-catalyzed reaction by ligands ()-1 and (+)-3
was independently confirmed in an enzymatic assay monitor-
ing the phosphorylation of the substrate [1,3,4-13C3]CDP-ME
(1 mm) by 13C NMR spectroscopy. The inhibitory mechanisms
for ()-1 and (+)-3 were subsequently determined, and evalua-
tion of the data using the computer program Dynafit[19] re-
vealed fully competitive inhibition, with Ki values in the upper
double-digit micromolar range (Table 1 and Supporting Infor-
mation Figure 6SI).
Prior to this work, two X-ray crystal structures of IspE were
available, one from the apo-enzyme of Thermus thermophilus
(1.7 N resolution, RCSB Protein Data Bank (PDB) code: 1UEK),[20]
and the other from the ternary complex of E. coli IspE bound
to CDP-ME and 5’-adenyl-b,g-amidotriphosphate (AppNp), a
non-hydrolyzable ATP analogue (2.0 N resolution, PDB code:
1JO4, Supporting Information Figure 7SI).[21] The structures re-
vealed that IspE contains three main binding pockets: the ade-
nosine binding, the cytidine binding, and the 2C-methyl-d-er-
ythritol-2-phosphate (MEP) binding pockets (Supporting Infor-
mation Figure 7SI). The fact that ()-1 and (+)-3 are competi-
tive inhibitors with respect to the substrate indicates that the
cytidine moiety is probably located in the homonymous
pocket, in agreement with molecular modeling predictions
using the program MOLOC.[22] This pocket does not provide
space to accommodate the butyl substituent on the exocyclic
amino group of the nucleobase, and this explains the lack of
binding of ()-2 and (+)-4. Furthermore, the weak affinity sug-
gests that little if any binding free enthalpy is gained from the
benzimidazole component and that the majority of the affinity
may indeed come from the nucleobase. The benzimidazole
moiety is far too large to occupy the small, hydrophobic sub-
pocket near the MEP binding pocket, which was more optimal-
ly filled with smaller residues such as cyclopropyl rings, with a
substantial gain in binding free enthalpy.[10] On the other hand,
we detected no binding of cytidine, CMP, CDP, or CTP within
the limits of our assay. To verify these hypotheses and to fur-
ther investigate the binding modes of inhibitors ()-1 and
(+)-3, X-ray crystallographic studies of co-crystals were under-
taken.
X-ray crystallography
Two crystal structures of IspE have been reported,[20,21] howev-
er it is difficult to obtain crystals with these proteins for ligand
binding studies. The enzyme from A. aeolicus has been found
to be more reliable in this respect and provided co-crystals
with ()-1 and (+)-3 suitable for X-ray analysis.
The structures of complexes of ()-1 (Figure 2 and Support-
ing Information Figure 8SI) and (+)-3 (Supporting Information
Figures 9SI and 10SI) with A. aeolicus IspE were determined to
2.4 N and 2.3 N resolution, respectively. The complexes are iso-
morphous and contain two molecules in the asymmetric unit
that are related by a non-crystallographic twofold axis. The sur-
face area between the two molecules is approximately 540 N2
per molecule, only 4% of the total surface area of the protein.
This low value is consistent with gel filtration and ultracentrifu-
gation experiments (data not shown) that indicate the enzyme
is a monomer in solution.[24] Overall, the secondary structure of
A. aeolicus IspE is similar to that of E. coli[21] and T. thermophilus
IspE.[20]
The complexes of ()-1 and (+)-3 with A. aeolicus IspE con-
firm that the cytidine moieties of both inhibitors are held in
the cytidine binding pocket, as suggested by molecular model-
ing[22] of these inhibitors docked into the active site of E. coli
IspE. In the solved X-ray crystal structures, the cytosine base is
H bonded to the side chain and backbone of His25 and the
backbone carbonyl of Lys145. In addition, it is placed at the
center of a p sandwich made of Tyr24 and Tyr175 (see Fig-
ure 2a and Supporting Information Figure 9SI). The presence
of a second H bond between the exocyclic amine of the cyto-
sine and the backbone carbonyl of Lys145 in A. aeolicus IspE
explains the absence of inhibitory activity of compounds ()-2
and (+)-4 (Figure 1). The butyl chain at this position prevents
formation of this H bond and leads to steric clashes with resi-
dues in this region of the active site, rather than providing ad-
ditional hydrophobic contacts. Unlike the nucleobase, the
ribose moiety of the ligands is not involved in strong interac-
tions with the active site residues.
The independent views of the active site in the complex
with ()-1 reveal two conformations of the benzimidazole
moiety, neither of which is well ordered. The group does not
occupy the MEP binding pocket (Figure 2b) or the adenosine
binding pocket (Figure 2c). Furthermore, the benzimidazole
moiety in active site A (Figure 2) does not adopt exactly the
same conformation as that observed in active site B (Support-
ing Information Figure 8SI). The lack of order and observation
of different conformations for this part of the ligands may indi-
cate a lack of specificity, and further suggest this group proba-
bly does not contribute significantly to binding affinity.
In the complex with (+)-3, the benzimidazole moiety is not
involved in any additional interactions that could explain its









[a] Ki=competitive inhibition constant. [b] IC50 values were determined at
[CDP-ME]=1 mm. [c] Not determined. [d] No inhibition of the IspE-cata-
lyzed reaction observed at [inhibitor]=2 mm.
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marginally higher affinity relative to inhibitor ()-1 (Table 1).
Again, the benzimidazole moiety occupies two very different
locations in the active site, neither in the MEP nor in the ade-
nine binding pockets, and is poorly ordered. In active site A,
the benzimidazole is near residues Ser170–Thr171 (Supporting
Information Figure 9SI) and in active site B it appears to adopt
an almost collapsed conformation, with the benzimidazole
moiety near residues Ala129 and Asp130 (Supporting Informa-
tion Figure 10SI).
Ammonium sulfate ((NH4)2SO4) and glycerol were required
for co-crystallization of the inhibitors and the protein. As they
were not added under the enzyme assay conditions, they are
not thought to be required for binding of the inhibitors. Both
crystal structures contain a number of sulfate ions in the two
active sites, providing valuable structural information on the
recognition of these anions (described in detail in the Support-
ing Information, Figures 8SI–10SI).[25]
The presence of these sulfate ions in the P-loop, usually
used to accommodate the much larger triphosphate moiety of
ATP, indicates that the loop is generally well organized, even in
the absence of ATP or an ATP analogue. The knowledge
gained on the pre-organization of this phosphate binding loop
could be exploited in second-generation inhibitors by directing
fragments with multiple H-bond acceptor sites into the loop,
as proposed previously.[26]
Comparisons of IspE from different organisms
The two protein–inhibitor co-crystal structures revealed three
important insights. First, the benzimidazole moiety of the li-
gands is poorly ordered in the active site. This suggests only a
minor contribution to the binding free enthalpy. Second, the
cytidine binding pocket and its interactions with the nucleo-
base are highly conserved. Finally, the Gly-rich P-loop involved
in cofactor binding seems to be well conserved and well or-
dered, even in the absence of ATP or an ATP analogue.
To date, the ternary complex of E. coli IspE has been success-
fully used for modeling, producing the first inhibitors of IspE
from this organism.[10] However, small structural differences be-
tween the enzyme of the E. coli model system and the enzyme
of the targeted organisms, that is, M. tuberculosis and P. falci-
parum, became apparent upon examination of the A. aeolicus
IspE complexes with inhibitors ()-1 and (+)-3. A detailed
comparison of the E. coli and A. aeolicus IspE structures will be
reported elsewhere, although at this stage, we would like to
point out that in terms of substrate and co-factor binding, the
two enzymes are highly similar.[24] It was deemed crucial, for
ongoing projects, to compare the active site residues among
the M. tuberculosis, P. falciparum, A. aeolicus, and E. coli homo-
logues, specifically focusing on the small, hydrophobic pocket
filled by cyclopropyl and similarly sized residues in the first-
generation E. coli IspE inhibitors.[10] The comparison revealed
that in general the overall architecture of the active site is
likely well conserved across the different organisms, with the
exception of a few, but important, variations in active site
amino acid residues (for a sequence alignment of IspE homo-
Figure 2. Binding mode of inhibitor ()-1 in the active site of A. aeolicus IspE
(PDB code: 2V2Q) as determined by X-ray crystallography to 2.4 N resolu-
tion. a) Schematic representation of the binding mode of ()-1 as observed
in active site A. H bonds are represented as red dashed lines. Distances be-
tween heavy atoms are given in N. b) Superposition of CDP-ME as observed
in active site A of E. coli IspE (PDB code: 1OJ4)[21] onto ()-1 as observed in
active site A of A. aeolicus IspE. The sulfate ion is in the position of the b-
phosphate of CDP-ME, and the benzimidazole moiety is oriented out of the
MEP pocket. c) Superposition of AppNp, as observed in active site A of E. coli
IspE (PDB code: 1JO4)[21] onto ()-1 as observed in active site A of A. aeolicus
IspE. The glycerol is located near the adenine binding region of the active
site. Color code: substrate skeleton: C: green; inhibitor skeleton: C: orange;
protein skeleton: C: grey; O: red; N: blue; S: yellow; P: cyan. All figures were
generated with the molecular graphics program Chimera.[23]
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logues from several organisms, see Supporting Information
Figure 11SI).
A simplified comparison of the active site residues of IspE
from M. tuberculosis, P. falciparum, A. aeolicus, and E. coli is de-
picted in Figure 3. As expected, the important catalytically
active residues Lys10 and Asp141 in the MEP pocket, are fully
conserved among the various organisms (Figure 3a), however
this trend changes in the cytidine pocket. In E. coli IspE, the cy-
tosine base H bonds to the backbone and side chain of His26.
While in M. tuberculosis and A. aeolicus IspE nucleobase recog-
nition is also achieved by His, in P. falciparum, this amino acid
is replaced by Asn, which can be considered an isosteric re-
placement. The ribose moiety of the substrate in E. coli IspE is
anchored by H bonding to Lys186 and by hydrophobic interac-
tions through its positioning at the center of a pseudo p sand-
wich composed of Tyr25 and Pro182. Whereas the tyrosine
residue is widely conserved among the various organisms, the
Pro residue is replaced by Lys (P. falciparum), Ser (M. tubercu-
losis), or Gly (A. aeolicus) (Figure 3a and Supporting Informa-
tion Figure 11bSI). Additional stabilization of the substrate in
the E. coli protein is derived from placing the cytosine at the
center of a p sandwich formed by the highly conserved aro-
matic amino acids Tyr25 and Phe185.[10] The small hydropho-
bic pocket in E. coli IspE, which was successfully filled by the
first-generation inhibitors (with Ki values down to the upper
nanomolar range),[10] is lined by Leu15, Leu28, and Phe185,
the latter of which is engaged in the p sandwich described
above. While Leu15 is fully conserved among the various or-
ganisms, Leu28 is conserved in M. tuberculosis, but replaced by
Val in P. falciparum or Ile in A. aeolicus, both of which can be
considered to be of similar steric demand (Figure 3a and Sup-
porting Information Figure 11aSI). On the other hand, replace-
ment of the highly hydrophobic Phe185 in E. coli IspE with a
more hydrophilic tyrosine residue in M. tuberculosis, P. falci-
parum, and A. aeolicus (Figure 3a and Supporting Information
Figure 11bSI) should affect the binding characteristics of this
pocket. In the structures of the complexes of A. aeolicus report-
ed herein, the OH group of tyrosine points directly into this
small pocket, thereby strongly decreasing its hydrophobic
character. This important observation could assist future
rounds of design and synthesis to improve on the first-genera-
tion inhibitors, especially with regard to their activity against
the targeted IspE proteins from M. tuberculosis and P. falci-
parum.
Conclusions
We have reported the synthesis, in vitro evaluation, and co-
crystal structures of two fully water-soluble nucleoside-based
inhibitors of IspE. Biological assays revealed competitive inhibi-
tion of E. coli IspE with Ki values in the upper double-digit mi-
cromolar range. The presumed binding modes of the nucleo-
base portion of ()-1 and (+)-3 were largely confirmed by
analysis of co-crystal structures obtained with A. aeolicus IspE,
a protein that seems to lend itself well to protein–ligand co-
crystallization. These first reported co-crystal structures of IspE
with synthetic ligands suggest that the majority, if not all, of
the affinity of the ligands for IspE is derived from the cytidine
portion. The benzimidazole moiety is poorly ordered and can
adopt different orientations, with poor intermolecular contacts
in the active site, thereby making only a small contribution to
the binding affinity. The crystal structures revealed defined
binding sites for sulfate ions and glycerol molecules, used as
components in the crystallization buffer, near the well-con-
served ATP binding Gly-rich loop of IspE. We intend to exploit
this loop for gaining additional docking interactions with next-
Figure 3. A comparison of the key amino acid residues of E. coli IspE (PDB code: 1JO4;[21] left non-bolded) with those of IspE from A. aeolicus (right non-
bolded), M. tuberculosis (left bold), and P. falciparum (right bold) in a) cytidine and MEP binding pockets and b) adenosine binding pocket. Numbering is ac-
cording to E. coli IspE protein.
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generation inhibitors. For our work targeting the inhibition of
IspE from P. falciparum and M. tuberculosis, it was important to
find that an OH group of a tyrosine side chain of A. aeolicus
IspE is directed into the small hydrophobic cavity. This is the
same hydrophobic cavity that we had filled with cyclopropyl
and related residues in our first-generation inhibitors of E. coli
IspE, in which this tyrosine is replaced with phenylalanine.[10] A
comparison among various organisms showed that IspE from
P. falciparum and M. tuberculosis, similar to A. aeolicus, also fea-
tures a tyrosine directing the OH group into the small pocket.
Therefore, the presented structures of A. aeolicus IspE should
be particularly useful for future structure-based lead design
targeting the parasite enzymes.
Experimental Section
General. N-Acetylcytidine[27] and 10[17] were prepared according to
published procedures. Reagents and solvents were purchased re-
agent-grade and used without further purification. (+)-Cytidine
was purchased from Acros Organics, and 2-benzimidazolepropionic
acid (11), from Aldrich. THF was freshly distilled from sodium ben-
zophenone ketyl. All reactions were performed in oven-dried glass-
ware under N2 atmosphere unless otherwise stated. Evaporation
and concentration in vacuo were performed at 40 8C and
~10 Torr. Further drying of the new compounds was carried out at
~102 Torr. TLC: pre-coated SiO2 60 F254 glass plates from Merck,
visualization by UV light (254 or 366 nm) or by staining with a solu-
tion of ninhydrin. Flash chromatography (FC): SiO2 60 (0.04–
0.063 mm) from Fluka with a head pressure of ~0.2 bar. Analytical
HPLC was performed on a Knauer Prontosil 120 C18 column (259P
4 mm, 5 mm, 100 N); products were eluted with CH3CN in H2O con-
taining 0.1% TFA at a flow rate of 1 mLmin1 and with UV detec-
tion at l=254 nm. Preparative HPLC was performed on a Knauer
Prontosil 120-5 C18 column (250P25 mm, 7 mm, 100 N); products
were eluted with CH3CN in H2O containing 0.1% TFA at a flow rate
of 10 mLmin1 and with UV detection at l=254 nm. Uncorrected
melting points (mp) were determined in an open capillary using a
BQchi Melting Point B540 apparatus. NMR (1H or 13C): Bruker AMX-II
500, Bruker AMX-II 300, Varian Mercury XL, or Gemini 300 NMR
spectrophotometers at 298 K. Residual solvent peaks were used as
an internal reference. Coupling constants (J) (H,H) are given in Hz.
Coupling patterns are designated as singlet (s), doublet (d), triplet
(t), quadruplet (q), quintuplet (qt), multiplet (m), or broad signal
(br). IR spectra: PerkinElmer 1600-FTIR or PerkinElmer Spectrum BX
FT-IR spectrophotometer, measured as a film (NaCl plates) or neat.
FT-ICR-MALDI-MS: Ion Spec Ultima FT-ICR-MS (337 nm N2 laser
system). Matrix : 3-HPA (3-hydroxypicolinic acid) ; the detected
masses are given as m/z with M representing the molecular ion. El-
emental analyses were performed by the Mikrolabor at the Labora-
torium fQr Organische Chemie, ETH ZQrich. Cytidine moieties are la-
beled according to convention; for the arbitrary labeling of residu-
al molecular fragments, see Supporting Information Figure 12SI.
General procedure A for coupling reactions : A solution of the
amine (1.0 equiv) and Et3N (1.0 equiv) in anhydrous DMF (0.15m)
was added dropwise to a stirred solution of the corresponding
acid (1.0 equiv), HOBt (1.0 equiv), and HBTU (1.0 equiv) in anhy-
drous DMF (0.1m) at 20 8C. After 18 h, the volatiles were removed
in vacuo, and the residue was purified by FC. The protected inter-
mediates were carried through to the next step according to gen-
eral procedure B without further characterization.
General procedure B for removal of protecting groups : TFA
(30%) was added dropwise to a stirred solution of the products
obtained from general procedure A in CH3CN/H2O 1:1 at 20 8C.
After 2 h, the volatiles were removed in vacuo, and the crude resi-




3,1-benzimidazol-1-ium bis(trifluoroacetate) (()-1): General pro-
cedure A, starting from the amine (+)-9 (117 mg, 0.20 mmol) and
Et3N (28 mL, 0.20 mmol) in anhydrous DMF (1.6 mL) and 10
[17]
(35 mg, 0.20 mmol), HOBt (28 mg, 0.20 mmol), and HBTU (78 mg,
0.20 mmol) in anhydrous DMF (1.60 mL). FC (Et3N/MeOH/AcOEt
1:10:89) afforded the protected intermediate (36 mg, 47%), which
was taken directly to the next step without further characteriza-
tion. General procedure B, starting from this intermediate and TFA
(0.50 mL) in CH3CN/H2O 1:1 (1.6 mL). RP HPLC (1:99 (10 min)!
35:65 (20 min)!100%, H2O with 0.1% TFA/CH3CN), followed by
lyophilization of the aqueous phases afforded the bis-TFA salt of
()-1 (38.6 mg, 31% over two steps). White powder; mp: 144–
145 8C; [a]20D =1.6 (c=0.5, MeOH); 1H NMR (300 MHz, CD3OD): d=
2.66 (s, 2H, H-C8), 3.60 (dd, J=13.8, 2.4 Hz, 1H, Ha-C5’), 3.67 (dd,
J=13.8, 6.3 Hz, 1H, Hb-C5’), 4.03–4.08 (m, 2H, H-C3’ and H-C4’),
4.26–4.31 (m, 1H, H-C2’), 5.69 (d, J=3.6 Hz, 1H, H-C1’), 6.10 (d, J=
7.8 Hz, 1H, H-C5), 7.56–7.61 (m, 2H, H-C13), 7.75–7.81 (m, 2H, H-
C12), 8.02 ppm (d, J=7.8 Hz, 1H, H-C6); 13C NMR (75 MHz, CD3OD):
d=42.21 (C8), 43.84 (C5’), 72.04 (C3’), 74.07 (C2’), 83.80 (C4’), 94.41
(C1’), 94.78 (C5), 114.66 (C12), 127.27 (C13), 132.14 (C11), 147.06
(C6), 148.62 (C2), 148.92 (C9), 161.38 (C4), 166.85 ppm (C7); IR
(neat): n˜=3251w, 3075w, 2930w, 2777w, 1663s (br), 1561w, 1540w,
1460w, 1425w, 1297w, 1261w, 1184s (br), 1130s (br), 1070w, 944w,
887w, 834m, 798 m, 750m, 721s cm1; HR-MALDI-MS (3-HPA): calcd
for C18H21N6O5
+ ([M+H]+): 401.1568, found: 401.1561.
2-{2-[({(2R,3S,4R,5R)-5-[4-(Butylammonio)-2-oxopyrimidin-1(2H)-
yl]-3,4-dihydroxytetrahydrofuran-2-yl}methyl)amino]-2-oxoeth-
yl}-1H-3,1-benzimidazol-1-ium bis(trifluoroacetate) (()-2): Gen-
eral procedure A, starting from amine (+)-13 (50 mg, 0.15 mmol)
and Et3N (21 mL, 0.15 mmol) in anhydrous DMF (1 mL) and 10
[17]
(26 mg, 0.15 mmol), HBTU (56 mg, 0.15 mmol), and HOBt (20 mg,
0.15 mmol) in anhydrous DMF (1.5 mL). FC (Et3N/MeOH/AcOEt
1:10:89) afforded the protected intermediate (28.5 mg, 38%),
which was taken directly to the next step without further charac-
terization. General procedure B, starting from this intermediate and
TFA (0.37 mL) in CH3CN/H2O (1:1, 1.2 mL). RP HPLC (5:95 (10 min)!
35:65 (20 min)!100% H2O with 0.1% TFA/CH3CN), followed by
lyophilization of the aqueous phases afforded the bis-TFA salt of
()-2 (29.6 mg, 29% over two steps) as a mixture of two conform-
ers denoted A and B (CD3OD, A/B=3:1). White powder; mp:
>128 8C (dec); [a]20D =17.5 (c=0.5, MeOH); 1H NMR (300 MHz,
CD3OD): d=0.97 (t, J=7.2 Hz, 6H, H-C10), 1.37–1.49 (m, 4H, H-C9),
1.65 (qt, J=7.2 Hz, 4H, H-C8), 3.40 (t, J=7.2 Hz, 4H, H-C7), 3.60–
3.75 (m, 4H, H-C5’), 4.02–4.10 (m, 4H, H-C3’ and H-C4’), 4.27–4.34
(m, 2H, H-C2’), 5.65 (d, J=3.0 Hz, 1H, HB-C1’), 5.70 (d, J=3.8 Hz,
1H, HA-C1’), 6.05 (d, J=7.8 Hz, 1H, HA-C5), 6.29 (d, J=8.1 Hz, 1H,
HB-C5), 7.55–7.61 (m, 4H, H-C17), 7.75–7.80 (m, 4H, H-C16), 7.83 (d,
J=7.8 Hz, 1H, HA-C6), 8.08 ppm (d, J=8.1 Hz, 1H, HB-C6);
13C NMR
(125 MHz, CD3OD): d=13.89 (CB10), 13.92 (CA10), 20.77 (CB9), 20.94
(CA9), 31.34 (CA8), 31.86 (CB8), 42.22 (CB7), 42.61 (C5’), 43.11 (CA7),
44.16 (C12), 72.14 (CB3’), 72.42 (CA3’), 74.87 (CA2’), 74.94 (CB2’),
83.82 (CA4’), 84.08 (CB4’), 92.01 (CB1’), 95.56 (CA1’), 96.26 (CA5), 95.36
(CB5), 114.91 (C16), 127.38 (C17), 132.57 (C15), 144.14 (C6), 148.22
(C13), 149.21 (CA2), 151.92 (CB2), 160.63 (CB4), 160.87 (CA4),
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167.10 ppm (C11), (14 C signals buried); IR (neat): n˜=3261w,
3070w, 2935w, 2868w, 1734w, 1670s (br), 1590s (br), 1459w, 1430w,
1347w, 1277w, 1199s (br), 1131s (br), 1073m, 944w, 833m, 798m,
750 m, 721s cm1; HR-MALDI-MS (3-HPA): calcd for C22H29N6O5
+
([M+H]+): 457.2194, found: 457.2188.
1-[(2R,3R,4S,5R)-5-({[3-(1H-Benzimidazol-3-ium-2-yl)propanoyl]a-
mino}methyl)-3,4-dihydroxytetrahydrofuran-2-yl]-2-oxo-1,2-dihy-
dropyrimidin-4-aminium bis(trifluoroacetate) ((+)-3): General
procedure A, starting from the amine (+)-9 (88 mg, 0.15 mmol)
and Et3N (21 mL, 0.15 mmol) in anhydrous DMF (1 mL) and com-
mercially available 11 (28 mg, 0.15 mmol), HBTU (56 mg,
0.15 mmol), and HOBt (20 mg, 0.15 mmol) in anhydrous DMF
(1.5 mL). FC (Et3N/MeOH/AcOEt 1:10:89) afforded the protected in-
termediate (97.7 mg, 86%), which was taken directly to the next
step without further characterization. General procedure B, starting
from this intermediate and TFA (0.74 mL) in CH3CN/H2O (1:1,
2.12 mL). RP HPLC (1:99 (10 min)!35:65 (20 min)!100% H2O with
0.1% TFA/CH3CN), followed by lyophilization of the aqueous
phases afforded the bis-TFA salt of (+)-3 (49.9 mg, 51% over two
steps). White powder; mp: 136–137 8C; [a]20D =+27 (c=0.5, MeOH);
1H NMR (300 MHz, CD3OD): d=2.96 (t, J=6.9 Hz, 2H, H-C8), 3.36–
3.47 (m, 3H, H-C9 and Ha-C5’), 3.57 (dd, J=14.4, 7.8 Hz, 1H, Hb-
C5’), 3.88 (t, J=6.0 Hz, 1H, H-C3’), 3.95–4.01 (m, 1H, H-C4’), 4.16
(dd, J=5.1, 3.5 Hz, 1H, H-C2’), 5.58 (d, J=3.5 Hz, 1H, H-C1’), 6.51
(d, J=7.8 Hz, 1H, H-C5), 7.50–7.56 (m, 2H, H-C14), 7.68–7.72 (m,
2H, H-C13), 7.89 ppm (d, J=7.8 Hz, 1H, H-C6); 13C NMR (75 MHz,
CD3OD): d=23.35 (C9), 32.50 (C8), 42.03 (C5’), 72.18 (C3’), 75.01
(C2’), 83.86 (C4’), 93.55 (C1’), 94.62 (C5), 114.38 (C13), 127.02 (C14),
132.06 (C12), 146.42 (C6), 148.39 (C10), 154.83 (C2), 161.19 (C4),
172.65 ppm (C7); IR (neat): n˜=3261w, 3075w, 2925w, 1724w, 1662s
(br), 1571w, 1556w, 1541w, 1463w, 1429w (br), 1274w (br), 1188s
(br), 1130s (br), 1070w, 889w, 835w, 798m, 781w, 751m, 721s cm1;





yl}-1H-3,1-benzimidazol-1-ium bis(trifluoroacetate) ((+)-4): Gen-
eral procedure A, starting from the amine (+)-13 (50 mg,
0.15 mmol) and Et3N (21 mL, 0.15 mmol) in anhydrous DMF (1 mL)
and commercially available 11 (28 mg, 0.15 mmol), HBTU (56 mg,
0.15 mmol), and HOBt (20 mg, 0.15 mmol) in anhydrous DMF
(1.5 mL). FC (Et3N/MeOH/AcOEt 1:10:89) afforded the protected in-
termediate (71 mg, 93%), which was taken directly to the next
step without further characterization. General procedure B, starting
from this intermediate and TFA (0.66 mL) in CH3CN/H2O (1:1,
2.2 mL). RP HPLC (5:99 (10 min)!35:65 (20 min)!100% H2O with
0.1% TFA/MeCN), followed by lyophilization to afford the bis-TFA
salt of (+)-4 (41.1 mg, 39% over two steps) as a mixture two con-
formers denoted A and B (CD3OD, A/B=3:1). White powder; mp:
107–109 8C; [a]20D =+11.6 (c=0.5, MeOH);
1H NMR (300 MHz,
CD3OD): d=1.00 (t, J=7.2 Hz, 6H, H-C10), 1.39–1.51 (m, 4H, H-C9),
1.68 (qt, J=7.2 Hz, 4H, H-C8), 2.95 (t, J=6.9 Hz, 4H, H-C12), 3.39–
3.63 (m, 12H, H-C5’, H-C7, and H-C13), 3.87–3.92 (m, 2H, H-C4’),
3.96–4.02 (m, 2H, H-C3’), 4.17 (dd, J=5.4, 3.5 Hz, 2H, H-C2’), 5.56
(d, J=3.3 Hz, 1H, HB-C1’), 5.61 (d, J=3.5 Hz, 1H, HA-C1’), 6.00 (d,
J=7.8 Hz, 1H, HB-C5), 6.22 (d, J=8.1 Hz, 1H, HA-C5), 7.50–7.56 (m,
4H, H-C18), 7.67–7.74 (m, 4H, H-C17), 7.77 (d, J=7.8 Hz, 1H, HA-
C6), 7.98 ppm (d, J=8.1 Hz, 1H, HB-C6);
13C NMR (75 MHz, CD3OD):
d=13.69 (C10), 20.70 (C13), 23.35 (C9), 30.87 (C12), 31.61 (CB8),
32.46 (CA8), 41.90 (CB5’), 42.19 (CA5’), 43.42 (CA7), 44.02 (CB7), 72.11
(CB3’), 72.31 (CA3’), 74.98 (C2’), 83.75 (CA4’), 83.88 (CB4’), 91.50 (CB1’),
93.18 (CA1’), 94.13 (CB5), 95.45 (CA5), 114.40 (C17), 126.99 (C18),
132.078 (C16), 143.71 (C6), 149.21 (C14), 154.85 (C2), 158.96 (C4),
172.63 ppm (C7), (13 C buried); IR (neat): n˜=3266w, 3090w, 2935w,
2863w, 1929w, 1662s (br), 1558w, 1463w, 1425w, 1275w, 1198s,
1186s (br), 1127s (br), 1075m, 1055m, 833m, 798m, 751m,
720s cm1; HR-MALDI-MS (3-HPA): calcd for C23H31N6O5
+ ([M+H]+):
471.2350, found: 471.2353.
N4-Acetyl-2’,3’-O-isopropylidenecytidine (()-5):[28] Triethyl ortho-
formate (23 mL, 140 mmol) was added dropwise over 15 min to a
vigorously stirred suspension of N4-acetylcytidine (10.0 g,
35.0 mmol) and p-toluenesulfonic acid monohydrate (6.65 g,
35.0 mmol) in anhydrous acetone (70 mL). After 1 h, the solution
became clear and was neutralized with 28% NH4OH (aq), and the
volatiles were removed in vacuo. The residue was dissolved in H2O
(100 mL) and cooled to 0 8C. After 18 h, the resulting solid precipi-
tate was collected by filtration, washed with ice-cold H2O, and
dried to afford ()-5 (9.5 g, 83%). White powder; mp: 131 8C
(Ref. [28]: 125–129 8C); [a]20D =4.0 (c=0.5, MeOH); 1H NMR
(400 MHz, (CD3)2SO): d=1.29 (s, 3H, CH3), 1.49 (s, 3H, CH3), 2.10 (s,
3H, COCH3), 3.54–3.59 (m, 1H, Ha-C5’), 3.62–3.67 (m, 1H, Hb-C5’),
4.20 (dd, J=7.8, 3.8 Hz, 1H, H-C4’), 4.76 (dd, J=6.2, 3.8 Hz, 1H, H-
C3’), 4.87 (dd, J=6.2, 2.1 Hz, 1H, H-C2’), 5.09 (t, J=5.1 Hz, 1H, H-
O5’), 5.85 (d, J=2.1 Hz, 1H, H-C1’), 7.19 (d, J=7.5 Hz, 1H, H-C5),
8.22 (d, J=7.5 Hz, 1H, H-C6), 10.89 ppm (s, 1H, NHAc); 13C NMR
(100 MHz, (CD3)2SO): d=20.95 (CH3), 24.27 (CH3), 26.89 (COCH3),
58.43 (C5’), 80.49 (C3’), 84.71 (C2’), 87.61 (C4’), 93.40 (C1’), 96.52
(C5), 112.48 (CACHTUNGTRENNUNG(CH3)2), 146.41 (C6), 154.38 (C2), 162.60 (C4),
170.97 ppm (C8); HR-MALDI-MS (3-HPA): calcd for C14H19N3NaO6
+
([M+Na]+): 348.1166, found: 348.1170.
N4-Acetyl-5’-deoxy-5’-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-
2’,3’-O-(1-methylethylidene)cytidine ((+)-6): DIAD (3.63 mL,
18.45 mmol) was added dropwise to a stirred suspension of ()-5
(3.0 g, 9.23 mmol), PPh3 (4.83 g, 18.45 mmol), and phthalimide
(2.71 g, 18.45 mmol) in anhydrous DMF (46 mL) at 20 8C. After 18 h,
MeOH (10 mL) was added and the solution was stirred for an addi-
tional 1 h until the solution became clear and colorless. The vola-
tiles were removed in vacuo. FC (AcOEt/hexanes 1:1!AcOEt) af-
forded (+)-6 (2.95 g, 70%). White solid; mp: >244 8C (dec); [a]20D =
+97.3 (c=0.5, CHCl3) ;
1H NMR (300 MHz, CDCl3): d=1.31 (s, 3H,
CH3), 1.50 (s, 3H, CH3), 2.31 (s, 3H, COCH3), 3.97 (dd, J=14.1,
5.4 Hz, 1H, Ha-C5’), 4.15 (dd, J=14.1, 8.4 Hz, 1H, Hb-C5’), 4.44–4.50
(m, 1H, H-C4’), 4.96 (dd, J=6.6, 3.9 Hz, 1H, H-C3’), 5.17 (dd, J=6.3,
1.2 Hz, 1H, H-C2’), 5.56 (s, 1H, H-C1’), 7.47 (d, J=7.5 Hz, 1H, H-C5),
7.66–7.72 (m, 3H, H-C6 and H-C10), 7.79–7.82 (m, 2H, H-C9),
10.40 ppm (s, 1H, NHCOCH3);
13C NMR (75 MHz, CDCl3): d=25.11
(CH3), 25.30 (CH3), 27.06 (COCH3), 40.11 (C5’), 82.67 (C3’), 84.98
(C2’), 86.33 (C4’), 97.21 (C1’), 97.37 (C5), 113.96 (CACHTUNGTRENNUNG(CH3)2), 123.25
(C9), 131.81 (C8), 133.85 (C10), 147.27 (C6), 154.73 (C2), 163.67 (C4),
167.88 (C7), 171.22 ppm (COCH3); IR (neat): n˜=3309w, 2973w,
1788w, 1708s, 1662s, 1623m, 1549m, 1488s, 1439m, 1394s, 1317s,
1274w, 1233w, 1204s, 1155m, 1137m, 1088s, 1069s, 1039m, 1014m,
1002m, 967w, 944w, 882w, 869s, 801w, 790s, 727s, 718s cm1; HR-




methylethylidene)cytidine ((+)-7): A solution of 7m NH3/MeOH
(18 mL) was added dropwise over 1 h to a stirred solution of (+)-6
(1.46 g, 3.12 mmol) in MeOH/CH2Cl2 (1:1, 73 mL) at 20 8C. After 6 h,
the volatiles were removed in vacuo. FC (Et3N/MeOH/AcOEt
1:10:89) afforded (+)-7 (1.09 g, 85%). White powder; mp: >155 8C
(dec); [a]20D =+55 (c=0.5, CHCl3) ;
1H NMR (300 MHz, CD3OD): d=
1.30 (s, 3H, CH3), 1.46 (s, 3H, CH3), 3.98 (dd, J=13.8, 6.0 Hz, 1H, Hb-
C5’), 4.08 (dd, J=13.8, 7.4 Hz, 1H, Ha-C5’), 4.28–4.34 (m, 1H, H-C4’),
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4.95 (dd, J=6.2, 3.9 Hz, 1H, H-C3’), 5.11 (dd, J=6.2, 1.7 Hz, 1H, H-
C2’), 5.44 (d, J=1.7 Hz, 1H, H-C1’), 5.86 (d, J=7.4 Hz, 1H, H-C5),
7.60 (d, J=7.4 Hz, 1H, H-C6), 7.75–7.83 ppm (m, 4H, H-C9 and H-
C10); 13C NMR (75 MHz, CD3OD): d=25.19 (CH3), 27.13 (CH3), 40.83
(C5’), 83.69 (C3’), 85.93 (C2’), 86.20 (C4’), 95.72 (C1’), 96.77 (C5),
114.65 (CACHTUNGTRENNUNG(CH3)2), 123.74 (C9), 132.75 (C8), 134.92 (C10), 145.29 (C6),
157.32 (C2), 167.52 (C4), 169.06 ppm (C7); IR (neat): n˜=3341w,
3183w, 2992w, 2930w, 1773w, 1709s, 1644s, 1517m, 1488m, 1431w,
1374s, 1313w, 1282m, 1208w, 1157m, 1088s, 1057s, 1010m, 875m,
856m, 787s, 712s cm1; HR-MALDI-MS (3-HPA): calcd for
C20H21N4O6
+ ([M+H]+): 413.1456, found: 413.1445.
N4-[Bis(4-methoxyphenyl) ACHTUNGTRENNUNG(phenyl)methyl]-5’-deoxy-5’-(1,3-dioxo-
1,3-dihydro-2H-isoindol-2-yl)-2’,3’-O-(1-methylethylidene)cyti-
dine ((+)-8): Dimethoxytrityl chloride (0.986 g, 2.9 mmol) was
added to a solution of Et3N (0.405 mL, 2.9 mmol) and (+)-7 (1.2 g,
2.9 mmol) in anhydrous CH2Cl2 (5.5 mL) at 20 8C. After 1 h, the vola-
tiles were removed in vacuo. FC (Et3N/AcOEt 1:99) afforded (+)-8
(1.77 g, 85%). White foam; mp: 186–188 8C (dec); [a]20D =+7.5 (c=
0.5, CHCl3) ;
1H NMR (300 MHz, CDCl3): d=1.30 (s, 3H, CH3), 1.48 (s,
3H, CH3), 3.80 (s, 6H, OCH3), 4.02–4.16 (m, 2H, H-C5’), 4.35–4.41 (m,
1H, H-C4’), 4.98 (dd, J=6.2, 3.6 Hz, 1H, H-C3’), 5.04 (d, J=7.2 Hz,
1H, H-C5), 5.20 (d, J=6.2 Hz, 1H, H-C2’), 5.39 (s, 1H, H-C1’), 6.84 (d,
J=8.7 Hz, 4H, H-C13), 6.98 (d, J=7.5 Hz, 1H, H-C6), 7.15 (d, J=
8.9 Hz, 4H, H-C14), 7.22–7.34 (m, 5H, Ph), 7.68–7.73 (m, 2H, H-C10),
7.80–7.84 ppm (m, 2H, H-C9); 13C NMR (75 MHz, CDCl3): d=25.38
(CH3), 27.12 (CH3), 40.39 (C5’), 55.32 (OCH3), 70.19; 83.05 (C3’),
84.96 (C2’), 85.94 (C4’), 94.81 (C1’), 96.91 (C5), 113.54, 113.73 (C-
ACHTUNGTRENNUNG(CH3)2), 123.23 (C9), 127.38, 128.27, 128.46, 129.84, 132.01 (C8),
133.79 (C10), 136.16, 143.47, 144.38 (C6), 154.72, 158.55 (C2),
165.80 (C4), 167.90 ppm (C7); IR (neat): n˜=2934w, 1774w, 1714w,
1652s, 1634s, 1582w, 1490s, 1463m, 1439w, 1392m, 1370 m,
1299w, 1294w, 1248s, 1209w, 1178s, 1158w, 1087m, 1055m, 1031s,
875w, 828w, 785w, 723m, 712m cm1; HR-MALDI-MS (3-HPA): calcd
for C41H38N4NaO8
+ ([M+Na]+): 737.2582, found: 737.2583.
5’-Amino-N4-[bis(4-methoxyphenyl)ACHTUNGTRENNUNG(phenyl)methyl]-5’-deoxy-
2’,3’-O-(1-methylethylidene)cytidine ((+)-9): n-Butylamine (5.5 mL,
55 mmol) was added to a solution of (+)-8 (1.7 g, 2.38 mmol) in
MeOH (32 mL), and the solution was heated at 60 8C. After 5 h, the
solution was cooled to 20 8C, and the volatiles were removed in va-
cuo. FC (Et3N/MeOH/AcOEt 1:10:89) afforded (+)-9 (1.2 g, 87%).
Positive ninhydrin test. White powder; mp: 172–1748 ; [a]20D =+31.5
(c=0.5, CHCl3) ;
1H NMR (300 MHz, CDCl3): d=1.31 (s, 3H, CH3), 1.51
(s, 3H, CH3), 3.17–3.29 (m, 2H, H-C5’), 3.79 (s, 6H, OCH3), 4.17–4.22
(m, 1H, H-C4’), 4.98 (dd, J=6.3, 4.2 Hz, 1H, H-C3’), 5.06–5.10 (m,
2H, H-C2’ and H-C5), 5.28 (d, J=2.1 Hz, 1H, H-C1’), 6.82 (d, J=
8.4 Hz, 4H, H-C9), 6.96 (d, J=7.8 Hz, 1H, H-C6), 7.13 (d, J=8.4 Hz,
4H, H-C10), 7.19–7.33 ppm (m, 5H, Ph); 13C NMR (75 MHz, CDCl3):
d=25.39 (CH3), 27.30 (CH3), 42.25 (C5’), 55.32 (OCH3), 70.37, 81.28
(C3’), 84.16 (C2’), 86.53 (C4’), 95.31 (C1’), 97.63 (C5), 113.58 (C7),
114.24 (CACHTUNGTRENNUNG(CH3)2), 127.43, 128.29, 128.44, 129.83, 135.84, 143.97,
144.55, 155.17 (C2), 158.60 (C6), 165.90 ppm (C4); IR (neat): n˜=
3200w, 1656m, 1632s, 1582w, 1491s, 1460m, 1371w, 1295w, 1248s,
1210m, 1178m, 1158m, 1083m, 1068m, 1031m, 829m, 785w, 753w,
701w cm1; HR-MALDI-MS (3-HPA): calcd for C33H36N4NaO6
+
([M+Na]+): 607.2527, found: 607.2529.
N4-(tert-Butoxycarbonyl)-5’-deoxy-5’-(1,3-dioxo-1,3-dihydro-2H-
isoindol-2-yl)-2’,3’-O-(1-methylethylidene)cytidine ((+)-12): Di-
tert-butyl carbonate (0.78 mL, 3.4 mmol) in dioxane (17 mL) was
added dropwise to a solution of (+)-7 (0.7 g, 1.7 mmol) in THF
(17 mL), and the mixture was heated at 70 8C. After 6 h, MeOH/H2O
(1:1, 5 mL) was added, and the volatiles were removed in vacuo.
FC (AcOEt/hexanes 1:1) afforded (+)-12 (0.779 g, 90%). White
powder; mp: 192–193 8C; [a]20D =+132 (c=0.5, CHCl3) ;
1H NMR
(300 MHz, CDCl3): d=1.34 (s, 3H, CH3), 1.52 (s, 12H, C ACHTUNGTRENNUNG(CH3)3 and
CH3), 4.00 (dd, J=13.8, 5.0 Hz, 1H, Ha-C5’), 4.19 (dd, J=13.8, 7.8 Hz,
1H, Hb-C5’), 4.48 (qt, J=5.0 Hz, 1H, H-C4’), 4.97 (dd, J=6.3, 3.6 Hz,
1H, H-C3’), 5.19 (dd, J=6.3, 1.1 Hz, 1H, H-C2’), 5.58 (d, J=1.1 Hz,
1H, H-C1’), 7.23 (d, J=7.5 Hz, 1H, H-C5), 7.42 (s br, 1H, NHBoc),
7.65–7.70 (m, 3H, H-C6 and H-C10), 7.81–7.84 ppm (m, 2H, H-C9);
13C NMR (75 MHz, CDCl3): d=25.37 (CH3), 27.09 (CH3), 28.12 (C-
ACHTUNGTRENNUNG(CH3)3), 40.24 (C5’), 82.71 (C3’) or (CACHTUNGTRENNUNG(CH3)3), 82.90 (C3’) or (CACHTUNGTRENNUNG(CH3)3),
85.07 (C2’), 86.30 (C4’), 95.05 (C1’), 97.08 (C5), 113.99 (CACHTUNGTRENNUNG(CH3)2),
123.26 (C9), 131.88 (C8), 133.81 (C10), 146.43 (C6), 150.94 (C2),
154.67 (COOCACHTUNGTRENNUNG(CH3)3), 162.67 (C4), 167.88 ppm (C7); IR (neat): n˜=
3302w, 2977w, 1772w, 1739m, 1718s, 1672m, 1628m, 1546w,
1489m, 1432w, 1392m, 1356w, 1339w, 1321w, 1280w, 1225m,
1164m, 1142s, 1089m, 1053s, 1002w, 986m, 966m, 883m, 853m,
809m, 789s, 764m, 724m, 712s cm1; HR-MALDI-MS (3-HPA): calcd
for C25H29N4O8
+ ([M+H]+): 513.1980, found: 513.1983; Anal. calcd
for C25H28N4O8 (512.51): C 58.59, H 5.51, N 10.93; found: C 58.74, H
5.72, N 10.73.
5’-Amino-N4-butyl-5’-deoxy-2’,3’-O-(1-methylethylidene)cytidine
((+)-13): n-Butylamine (0.54 mL, 5.44 mmol) was added to a solu-
tion of (+)-12 (0.70 g, 1.36 mmol) in EtOH (18 mL), and the solution
was heated at 70 8C. After 6 h, the temperature was increased to
75 8C and stirring was continued. After an additional 2 h, the solu-
tion was cooled to 20 8C, and the volatiles were removed in vacuo.
FC (Et3N/MeOH/AcOEt 1:10:89) afforded (+)-13 (0.375 g, 82%). Pos-
itive ninhydrin test. White foam; mp: 54–56 8C; [a]20D =+18.2 (c=
0.5, CHCl3) ;
1H NMR (300 MHz, CD3OD): d=0.94 (t, J=7.2 Hz, 3H,
H-C10), 1.28–1.46 (m, 5H, H-C9), CH3), 1.52–1.61 (m, 5H, H-C8 and
CH3), 2.91 (d, J=1.8 Hz, 1H, Ha-C5’), 2.93 (d, J=3.0 Hz, 1H, Hb-C5’),
3.34 (q, J=7.2 Hz, 2H, H-C7), 4.01–4.06 (m, 1H, H-C4’), 4.75 (dd, J=
6.6, 4.5 Hz, 1H, H-C3’), 5.02 (dd, J=6.6, 2.4 Hz, 1H, H-C2’), 5.67 (d,
J=2.4 Hz, 1H, H-C1’), 5.80 (d, J=7.5 Hz, 1H, H-C5), 7.50 ppm (d,
J=7.5 Hz, 1H, H-C6); 13C NMR (75 MHz, CD3OD): d=13.88 (C10),
20.85 (C9), 25.33 (CH3), 27.30 (CH3), 31.82 (C8), 41.11 (C5’), 44.30
(C7), 82.64 (C3’), 85.42 (C2’), 88.47 (C4’), 95.64 (C1’), 96.72 (C5),
114.88 (CACHTUNGTRENNUNG(CH3)2), 143.16 (C6), 157.73 (C2), 165.14 ppm (C4); IR
(neat): n˜=3266w, 3121w, 2968w, 2951w, 2931w, 1637s, 1578m,
1505s, 1465m, 1432w, 1372m, 1318w, 1279m, 1211m, 1157m,
1065s, 969w, 941w, 876w, 858m, 785s cm1; HR-MALDI-MS (3-HPA):
calcd for C16H27N4O4
+ ([M+H]+): 339.2027, found: 339.2025.
In vitro assays
Materials. [1,3,4-13C3]4-Diphosphocytidyl-2C-methyl-d-erythritol
(CDP-ME) was prepared according to literature procedures.[18] E. coli
IspE was also obtained according to published procedures.[12b]
NADH and phosphoenolpyruvate potassium salt were purchased
from Biomol, ATP and pyruvate kinase/lactate dehydrogenase from
Sigma–Aldrich.
Enzyme-coupled photometric assay for IC50 determination. Assay
mixtures were prepared as described[18] with some modifications:
60 mL of a solution containing 100 mm Tris-HCl (pH 8.0), 10 mm
MgCl2, 2 mm dithiothreitol (DTT), 2.5 mm phosphoenolpyruvate po-
tassium salt, 2 mm ATP, 0.46 mm NADH, 1 U lactate dehydrogenase,
1 U pyruvate kinase, and IspE protein were added to 60 mL of the
inhibitor solutions (final concentration varied from 16 to 2000 mm).
The reaction was started by the addition of 60 mL of CDP-ME (final
concentration 1 mm) and monitored at 340 nm.
Enzyme-coupled photometric assay for Ki determination. Assay
mixtures were prepared as follows: 50 mL of a solution containing
100 mm Tris-HCl (pH 8.0), 10 mm MgCl2, 2 mm DTT, 2.5 mm phos-
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phoenolpyruvate potassium salt, 2 mm ATP, 0.46 mm NADH, 1 U
lactate dehydrogenase, 1 U pyruvate kinase, and 2.4 mU IspE pro-
tein were added to 50 mL each of the inhibitor solution. The reac-
tion was started by the addition of 50 mL CDP-ME. For the determi-
nation of each single KM value in the presence of the inhibitor, the
concentration of CDP-ME was varied from 35 to 400 mm, while
keeping the concentration of the inhibitor fixed. The mixtures
were incubated at 27 8C, and the reaction was monitored photo-
metrically at 340 nm. The Ki values of the inhibitors were obtained
by observing the behavior of KM values at various inhibitor concen-
trations (3–50 mm) and processing the data using the program Dy-
nafit.[19]
13C NMR assay. Assay mixtures contained 100 mm Tris-HCl (pH 8.0),
10 mm MgCl2, 5 mm ATP, 10% (v/v) D2O, 2 mm DTT, 1.5 mm [1,3,4-
13C3]CDP-ME, and 13 mg IspE protein in a volume of 500 mL. Inhibi-
tory substances were added at final concentrations ranging from 0
to 3 mm. The mixtures were incubated at 37 8C and terminated by
the addition of EDTA to a final concentration of 20 mm. The solu-
tion was analyzed by 13C NMR spectroscopy on a Bruker DRX 500
(125 MHz) and referenced to an internal standard of [1-13C1]glucose
(0.9 mm).
X-ray crystallography. Crystals of A. aeolicus IspE complexed with
()-1 and (+)-3 were obtained by the hanging-drop vapor-diffu-
sion method. Further details are included in the PDB depositions
(PDB codes: 2V2Q and 2V2V for the co-crystal structures with ()-1
and (+)-3, respectively). The enzyme was first incubated with each
ligand and AMP for 1 h at 4 8C prior to setting up drops. The reser-
voir solution was 1.6m (NH4)2SO4, 100 mm (CH3)2AsO2Na pH 6.5,
100 mm NaBr. The hanging drop consisted of 1 mL reservoir solu-
tion and 1 mL protein solution (30 mgmL1) in 10 mm Tris-HCl
pH 8.5, 20 mm NaCl, 1 mm DTT, 4 mm AMP, and 4 mm ligand. Crys-
tals were cryo-protected in a solution containing 20% glycerol,
and data were collected on a RaxisIV++ image plate detector cou-
pled to a Rigaku M007 rotating anode X-ray generator (Cu Ka, l=
1.5418 N), then processed using MOSFLM.[29] The crystals are cubic
pyramids in the space group P213 with unit cell dimensions a=b=
c=137.0 N for the complex with (+)-3, and a=b=c=137.3 N for
the complex with ()-1. The dataset for compound (+)-3 was
99.9% complete to 2.3 N resolution with an Rsym of 8.3%, 58.5% in
the outer resolution bin. The dataset for compound ()-1 was
99.9% complete to 2.4 N resolution with an Rsym of 8.2%, 58.1% in
the outer shell. The starting model for each analysis was the previ-
ously solved A. aeolicus IspE structure,[24] and molecular replace-
ment using MOLREP[30] was used to generate a model for refine-
ment. Rigid body refinement using REFMAC5[31] preceded a combi-
nation of model building in COOT[32] and restrained refinement
(REFMAC5) to an Rfactor and Rfree of 21.2% and 22.7% for compound
(+)-3, 21.7% and 27.2% for compound ()-1. The model for the
complex with compound (+)-3 consisted of 539 residues, 2 ligand
molecules, 348 water molecules, 5 sulfate anions, 7 bromide
anions, and 2 glycerol molecules; 98.0% of residues were in the
most favored regions of the Ramachandran plot (MOLPROBITY)[33]
with no residues in the disallowed regions. The complex with com-
pound ()-1 consisted of 540 residues, 2 ligand molecules,
264 water molecules, 5 sulfate anions, 8 bromide anions, and
3 glycerol molecules; 97.5% of residues were in the most favored
regions of the Ramachandran plot with 2 residues in the disal-
lowed regions. In both cases, atoms of the cytosine moiety of the
ligands were assigned full occupancy. The remaining atoms were
given zero occupancy to identify that the electron density associat-
ed with them was poorly defined.
Acknowledgements
We gratefully acknowledge financial support for this work from
the following agencies: ETH Research Council, the Munich Center
for Integrated Protein Science, the Hans-Fischer-Gesellschaft, the
Wellcome Trust (to W.N.H.), and the Biotechnology and Biological
Sciences Research Council (UK) (to W.N.H.).
Keywords: crystal structure analysis · drug design · inhibitors ·
kinases · non-mevalonate pathway
[1] a) M. Rohmer, M. Knani, P. Simonin, B. Sutter, H. Sahm, Biochem. J. 1993,
295, 517–524; b) M. K. Schwarz, No. 10951, PhD dissertation, ETH Zurich,
1994 ; c) S. T. J. Broers, No. 10978, PhD dissertation, ETH Zurich, 1994 ;
d) W. Eisenreich, B. Menhard, P. J. Hylands, M. H. Zenk, A. Bacher, Proc.
Natl. Acad. Sci. USA 1996, 93, 6431–6436; e) W. Eisenreich, M. Schwarz,
A. Cartayrade, D. Arigoni, M. H. Zenk, A. Bacher, Chem. Biol. 1998, 5,
R221–R233.
[2] Y. Boucher, W. F. Doolittle, Mol. Microbiol. 2000, 37, 703–716.
[3] a) F. Rohdich, J. Wungsintaweekul, M. Fellermeier, S. Sagner, S. Herz, K.
Kis, W. Eisenreich, A. Bacher, M. H. Zenk, Proc. Natl. Acad. Sci. USA 1999,
96, 11758–11763; b) F. Rohdich, S. Hecht, A. Bacher, W. Eisenreich, Pure
Appl. Chem. 2003, 75, 393–405.
[4] H. Jomaa, J. Wiesner, S. Sanderbrand, B. Altincicek, C. Weidemeyer, M.
Hintz, I. TQrbachova, M. Eberl, J. Zeidler, H. K. Lichtenthaler, D. Soldati, E.
Beck, Science 1999, 285, 1573–1576.
[5] http://www.cdc.gov/tb/WorldTBDay/resources_global.htm.
[6] a) U. Weiss, Nature 2002, 415, 669; b) J. K. Baird, N. Engl. J. Med. 2005,
352, 1565–1577; c) http://www.cdc.gov/malaria/impact/index.htm; d) M.
Schlitzer, ChemMedChem 2007, 2, 944–986.
[7] a) A. L. Kritski, L. S. Rodrigues de Jesus, M. K. Andrade, E. Werneck-Barro-
so, M. A. Vieira, A. Haffner, L. W. Riley, Chest 1997, 111, 1162–1167;
b) J. E. OllU-Goig, Trop. Med. Int. Health 2006, 11, 1625–1628.
[8] For some selected publications on fosmidomycin and derivatives, see:
a) T. Kuzuyama, T. Shimizu, S. Takahashi, H. Seto, Tetrahedron Lett. 1998,
39, 7913–7916; b) M. A. Missinou, S. Borrmann, A. Schindler, S. Issifou,
A. A. Adegnika, P.-B. Matsiegui, R. Binder, B. Lell, J. Wiesner, T. Baranek,
H. Jomaa, P. G. Kremsner, Lancet 2002, 360, 1941–1942; c) J. Wiesner, R.
Ortmann, H. Jomaa, M. Schlitzer, Angew. Chem. 2003, 115, 5432–5451;
Angew. Chem. Int. Ed. 2003, 42, 5274–5293; d) B. Lell, R. Ruangweerayut,
J. Wiesner, M. A. Missinou, A. Schindler, T. Baranek, M. Hintz, D. Hutchin-
son, H. Jomaa, P. G. Kremsner, Antimicrob. Agents Chemother. 2003, 47,
735–738; e) S. Oyakhirome, S. Issifou, P. Pongratz, F. Barondi, M. Ramhar-
ter, J. F. Kun, M. A. Missinou, B. Lell, P. G. Kremsner, Antimicrob. Agents
Chemother. 2007, 51, 1869–1871; f) N. Singh, G. Cheve, M. A. Avery, C. R.
McCurdy, Curr. Pharm. Des. 2007, 13, 1161–1177.
[9] W. N. Hunter, J. Biol. Chem. 2007, 282, 21573–21577.
[10] A. K. H. Hirsch, S. Lauw, P. Gersbach, W. B. Schweizer, F. Rohdich, W. Ei-
senreich, A. Bacher, F. Diederich, ChemMedChem 2007, 2, 806–810.
[11] a) C. M. Crane, J. Kaiser, N. L. Ramsden, S. Lauw, F. Rohdich, W. Eisen-
reich, W. N. Hunter, A. Bacher, F. Diederich, Angew. Chem. 2006, 118,
1082–1087; Angew. Chem. Int. Ed. 2006, 45, 1069–1074; b) C. Baumgart-
ner, C. Eberle, F. Diederich, S. Lauw, F. Rohdich, W. Eisenreich, A. Bacher,
Helv. Chim. Acta 2007, 90, 1043–1068.
[12] a) F. Rohdich, J. Wungsintaweekul, H. LQttgen, M. Fischer, W. Eisenreich,
C. A. Schuhr, M. Fellermeier, N. Schramek, M. H. Zenk, A. Bacher, Proc.
Natl. Acad. Sci. USA 2000, 97, 8251–8256; b) H. LQttgen, F. Rohdich, S.
Herz, J. Wungsintaweekul, S. Hecht, C. A. Schuhr, M. Fellermeier, S.
Sagner, M. H. Zenk, A. Bacher, W. Eisenreich, Proc. Natl. Acad. Sci. USA.
2000, 97, 1062–1067; c) T. Kuzuyama, M. Takagi, K. Kaneda, H. Wata-
nabe, T. Dairi, H. Seto, Tetrahedron Lett. 2000, 41, 2925- 2928.
[13] a) S. Herz, J. Wungsintaweekul, C. A. Schuhr, S. Hecht, H. LQttgen, S.
Sagner, M. Fellermeier, W. Eisenreich, M. H. Zenk, A. Bacher, F. Rohdich,
Proc. Natl. Acad. Sci. USA 2000, 97, 2486–2490; b) F. Rohdich, W. Eisen-
reich, J. Wungsintaweekul, S. Hecht, C. A. Schuhr, A. Bacher, Eur. J. Bio-
chem. 2001, 268, 3190–3197.
100 www.chemmedchem.org F 2008 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2008, 3, 91 – 101
MED F. Rohdich, W. N. Hunter, F. Diederich, et al.
[14] a) Y.-H. Woo, R. P. M. Fernandes, P. J. Proteau, Bioorg. Med. Chem. 2006,
14, 2375–2385; b) V. Devreux, J. Wiesner, J. L. Goeman, J. Van der
Eycken, H. Jomaa, S. Van Calenbergh, J. Med. Chem. 2006, 49, 2656–
2660; c) T. Haemers, J. Wiesner, S. Van Poecke, J. Goeman, D. Henschker,
E. Beck, H. Jomaa, S. Van Calenbergh, Bioorg. Med. Chem. Lett. 2006, 16,
1888–1891.
[15] a) T. Kuzuyama, M. Takagi, K. Kaneda, T. Dairi, H. Seto, Tetrahedron Lett.
2000, 41, 703–706; b) F. Rohdich, J. Wungsintaweekul, W. Eisenreich, G.
Richter, C. A. Schuhr, S. Hecht, M. H. Zenk, A. Bacher, Proc. Natl. Acad.
Sci. USA 2000, 97, 6451–6456; c) S. B. Richard, M. E. Bowman, W. Kwiat-
kowski, I. Kang, C. Chow, A. M. Lillo, D. E. Cane, J. P. Noel, Nat. Struct.
Biol. 2001, 8, 641–648; d) L. E. Kemp, C. S. Bond, W. N. Hunter, Acta Crys-
tallogr. Sect. D 2003, 59, 607–610.
[16] a) E. Sonveaux, Methods Mol. Biol. 1994, 26, 1–71; b) H. Weber, H. G.
Khorana, J. Mol. Biol. 1972, 72, 219–249.
[17] P. Vicini, M. Incerti, L. Amoretti, V. Ballabeni, M. Tognolini, E. Barocelli,
Farmaco 2002, 57, 363–367.
[18] V. Illarionova, J. Kaiser, E. Ostrozhenkova, A. Bacher, M. Fischer, W. Eisen-
reich, F. Rohdich, J. Org. Chem. 2006, 71, 8824–8834.
[19] P. Kuzmic, Anal. Biochem. 1996, 237, 260–273.
[20] T. Wada, T. Kuzuyama, S. Satoh, S. Kuramitsu, S. Yokoyama, S. Unzai,
J. R. H. Tame, S.-Y. Park, J. Biol. Chem. 2003, 278, 30022–30027.
[21] L. Miallau, M. S. Alphey, L. E. Kemp, G. A. Leonard, S. M. McSweeney, S.
Hecht, A. Bacher, W. Eisenreich, F. Rohdich, W. N. Hunter, Proc. Natl.
Acad. Sci. USA. 2003, 100, 9173–9178.
[22] a) P. R. Gerber, K. MQller, J. Comput.-Aided Mol. Des. 1995, 9, 251–268;
b) Gerber Molecular Design (http://www.moloc.ch).
[23] a) All molecular graphics images were produced using the UCSF Chi-
mera package from the Resource for Biocomputing, Visualization, and
Informatics at the University of California, San Francisco (supported by
NIH P41 RR-01081); For details, see: b) E. F. Pettersen, T. D. Goddard,
C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, T. E. Ferrin, J.
Comput. Chem. 2004, 25, 1605–1612; c) Chimera home page can be
found at http://www.cgl.ucsf.edu/chimera.
[24] T. Sgraja, M. S. Alphey, S. Ghilagaber, R. Marquez, W. N. Hunter, unpub-
lished results.
[25] a) J. W. Pflugrath, F. A. Quiocho, Nature 1985, 314, 257–260; b) H.
Luecke, F. A. Quiocho, Nature 1990, 347, 402–406; c) J. J. He, F. A. Quio-
cho, Science 1991, 251, 1479–1481.
[26] A. K. H. Hirsch, F. R. Fischer, F. Diederich, Angew. Chem. 2007, 119, 342–
357; Angew. Chem. Int. Ed. 2007, 46, 338–352.
[27] S. M. Marcuccio, B. C. Elmes, G. Holan, E. J. Middleton, Nucleosides Nucle-
otides 1992, 11, 1695–1701.
[28] a) J. P. H. Verheyden, J. G. Moffatt, J. Org. Chem. 1974, 39, 3573–3579;
b) K.-Y. Jung, R. J. Hohl, A. J. Wiemer, D. F. Wiemer, Bioorg. Med. Chem.
2000, 8, 2501–2509.
[29] A. G. W. Leslie, H. R. Powell, G. Winter, O. Svensson, D. Spruce, S.
McSweeney, D. Love, S. Kinder, E. Duke, C. Nave, Acta Crystallogr. Sect. D
2002, 58, 1924–1928.
[30] A. Vagin, A. Teplyakov, J. Appl. Crystallogr. 1997, 30, 1022–1025.
[31] G. N. Murshudov, A. A. Vagin, E. J. Dodson, Acta Crystallogr. Sect. D 1997,
53, 240–255.
[32] P. Emsley, K. Cowtan, Acta Crystallogr. Sect. D 2004, 60, 2126–2132.
[33] S. C. Lovell, I. W. Davis, W. B. Arendall III, P. I. W. de Bakker, J. M. Word,
M. G. Prisant, J. S. Richardson, D. C. Richardson, Proteins : Struct. Funct.
Gen. 2003, 50, 437–450.
Received: August 13, 2007
Published online on November 21, 2007
ChemMedChem 2008, 3, 91 – 101 F 2008 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.chemmedchem.org 101
Cytidine Derivative Inhibitors of IspE
